Melbourne, WHO Collaborating Centre for Viral Hepatitis and Doherty Institute, 2025. 49p.
Statistics for prevalence, diagnosis, engagement in care, treatment and deaths.
Adelaide, Cancer Council SA and Hepatitis SA, 2025. Video.
Brief information about hepatitis B, including transmission, symptoms, risk of liver cancer and vaccination. Available in Arabic, Amharic, English, French, Kirundi, Tigrinya, Somali, Swahili.
Melbourne, John Wiley and Son, 2025. 8p.
Universal screening of HBsAg-positive patients identified 11% more anti-HDV-positive patients in comparison to the AASLD-supported high-risk-only screening recommendations. Due to the paramount importance of HDV detection, universal HDV screening in HBsAg-positive patients is encouraged.
London, Springer Nature, 2025. 10p.
People who inject drugs (PWID) face a substantial risk of hepatitis C virus (HCV) infection, often in the context of multiple injecting partnerships. The disclosure of HCV status to injecting partners holds significant implications for prevention and care among PWID.
London, BMJ Group, 2025. 17p.
The current landscape of hepatitis B, including epidemiology, disease progression, screening and diagnosis, and an in-depth evaluation of antiviral treatment strategies.
Basel, MDPI, 2025. 26p.
Provides updates on recent advancements in HDV treatment including novel therapies.
Melbourne, John Wiley and Son, 2025. 13p.
People infected with both hepatitis B virus (HBV) and hepatitis Delta virus (HDV) face a higher mortality risk than those mono-infected with HBV. Study compared the effects of various behavioural factors on all-cause mortality among people with chronic hepatitis B (CHB), with or without chronic hepatitis Delta (CHD).
Zurich, INHSU, 2025. Webpage.
Discusses the types of law reform that have been implemented globally and how they compare to an ideal model which not only delivers improved health outcomes but corrects the long-standing injustice of the criminalisation of PWUD.
Sydney, Kirby Institute, 2024. 96p
This enhanced report is the first to specifically endeavour to report on BBVs and STIs among people from CALD backgrounds.
London, Springer Nature, 2024. 14p.
Explores the attitudes and beliefs, including stigma, about hepatitis B among students of Vietnamese and Chinese background in Australia. Students provide a point of entry to communities with high prevalence of hepatitis B, that otherwise may be hard to access.
London, Elsevier, 2024. 8p.
A targeted HCV education program for people in prison, addressing the gaps identified in this analysis, may enhance HCV testing, treatment, and prevention by fostering stronger HCV health literacy among people in prison.
London, Elsevier, 2025. 8p.
Feasibility study of point-of-care hepatitis C testing and rapid treatment initiation delivered adjacent to community corrections settings via a mobile, nurse and peer-led, low-threshold model of care.
London, Springer Nature, 2025. 11p.
In the Northern Territory (NT), First Nations people with chronic hepatitis B (CHB) are infected with a unique sub‐genotype, C4, which contains mutations linked to progressive fibrosis and hepatocellular carcinoma. This cohort study aimed to investigate disease progression in C4 sub‐genotype infection and estimate how many untreated individuals may benefit from antiviral therapy with broadening treatment indications. Only 6·7% of untreated individuals were treatment eligible under current guidelines. Using the 2024 World Health Organisation guidelines, this increased to 50% due mostly to fibrosis and population prevalence of diabetes.
London, Elsevier, 2024. 11p.
A suite of multi-modal resources addressing the perceived gaps in HCV health literacy was developed, with a broad theme of ‘Let's talk about hep C’. Peer education delivery was considered a key facilitator for custodial officers and people in prison.
London, Elsevier, 2025. 12p.
A multidisciplinary model of care increased linkage to HCV care among untreated individuals released from prison. Future interventions should support similar models, leveraging social support networks to maximize continuity of care.
For enquiries or feedback, please contact the librarian at Librarian@hepatitissa.asn.au.
| Address: | 3 Hackney Road Hackney SA 5069 |
| Phone: | (08) 8362 8443 |
| Fax: | (08) 8362 8559 |
| Email: | Librarian@hepatitissa.asn.au |
| Post: | PO Box 782 Kent Town SA 5071 |
Monday – Friday
9am to 5pm
Hepatitis SA is a non-profit, community-based organisation that provides information, education and support services to South Australians affected by hepatitis B and hepatitis C.